JUPITER - Crestor 20mg Versus Placebo in Prevention of Cardiovascular (CV) Events

• Status: Terminated
• Trial end date: 2008-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the safety and effectiveness of long-term therapy with rosuvastatin compared with a placebo, and to evaluate whether treatment with rosuvastatin might be effective in reducing the risk of major cardiovascular events.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: AstraZeneca
• Treatments: Rosuvastatin Calcium

Criteria

Inclusion Criteria:

• Men 50 years or older, women 60 years or older

• Low to normal levels of low density lipoprotein (LDL) cholesterol (< 130mg/dL)

• Elevated levels of C-Reactive Protein (CRP) > 2.0 mg/L

Exclusion Criteria:

• History of cardiovascular or cerebrovascular events

• Active liver disease

• Diabetes mellitus

• Uncontrolled hypertension or hypothyroidism

• History of certain malignancies

• Chronic inflammatory conditions

• History of alcohol or drug abuse